GLP-1 receptor agonist (once-daily)
A once-daily injectable GLP-1 medication approved for both type 2 diabetes and chronic weight management.
| Class / type | GLP-1 receptor agonist (once-daily) |
|---|---|
| Category | Metabolic & Weight |
| Status (Jul 2026) | FDA-approved |
Acts as a GLP-1 analog, enhancing glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying, and acting on brain appetite centers to reduce hunger.
FDA-approved for type 2 diabetes (Victoza) and for chronic weight management (Saxenda) in adults and certain adolescents.
Improves glycemic control, reduces appetite and body weight, and offers cardiovascular benefit in diabetic patients.
Frequent gastrointestinal side effects (nausea, vomiting, diarrhea), possible gallbladder issues and pancreatitis, and a boxed warning for thyroid C-cell tumors.
Users report reliable appetite suppression and steady weight loss, though some dislike the daily injection compared to weekly agents.
FDA-approved: marketed as Victoza (diabetes, 2010) and Saxenda (weight management, 2014); generic versions now available. The FDA is also winding down compounded versions.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.